home / press / releases

Menu
  • Search all tables

releases: https://buddycarter.house.gov/news/documentsingle.aspx?DocumentID=11547

One row per release. Full-text search runs over title + body text.

Data license: MIT · Data source: dwillis/congress-press

This data as json

url title date year month party chamber state member_name bioguide_id domain scraper source date_source text has_text collected_at updated_at
https://buddycarter.house.gov/news/documentsingle.aspx?DocumentID=11547 Carter, Matsui support patient’s access to telemedicine for vital prescriptions 2023-12-14 2023 2023-12 Republican House GA Earl L. "Buddy" Carter C001103 buddycarter.house.gov buddycarter https://buddycarter.house.gov/news/documentquery.aspx?DocumentTypeID=27 scraper WASHINGTON, D.C. – Reps. Earl L. “Buddy” Carter (R-GA) and Doris Matsui (D-CA) today sent a letter to Drug Enforcement Administration (DEA) Administrator Anne Milgram voicing support for the agency’s temporary rules allowing patients to continue to be prescribed controlled substances via telemedicine, as clinically appropriate, and advocating for swift issuance of a final rule that fulfills DEA’s mission while prioritizing patient access. In the letter, the Members write: “The pandemic has demonstrated the value of telehealth in increasing access to clinically appropriate care, and DEA now has the opportunity to continue the benefits of telehealth while ensuring operationally feasible guardrails…Health care providers, pharmacists, and patients deserve to have a formalized process focused on patient access to clinically appropriate care while allowing DEA to fulfill its enforcement obligations.” The Members continue: “We urge DEA to work diligently towards a finalized regulatory framework for the prescribing of controlled substances via telemedicine, understanding that time is of the essence…We are confident that a permanent regulatory framework for telemedicine prescribing can increase access to care.” This letter comes after delays from the DEA in creating a Special Registration for Telemedicine process, as mandated by Congress, and emphasizes the need for clarity as current protections for patients and providers expire on December 31, 2024. Read the full letter here. 1 2026-03-30T01:40:41Z 2026-04-08T01:14:16Z
Powered by Datasette · Queries took 0.992ms · Data license: MIT · Data source: dwillis/congress-press